Skip to main content Accessibility help
×
Home

Relationship of oestrogen receptor status to depressive symptoms and quality of life in breast cancer patients

  • Jong-Hoon Kim (a1), Byoung-Jo Lee (a2) (a3), Jae-Nam Bae (a4) and Bong-Jin Hahm (a2) (a5) (a6)

Abstract

Objective

We investigated the relationship of oestrogen receptor (ER) status to the severity of depressive symptoms and quality of life (QOL) impairment in breast cancer patients.

Methods

Seventy-seven breast cancer patients with comorbid depression were evaluated with the Hamilton Depression Rating Scale (HAMD), the Clinical Global Impression-Severity of Illness (CGI-S) for depression, and the Functional Assessment of Cancer Therapy-Breast (FACT-B). ER status was determined using immunohistochemical analysis.

Results

The ER-positive group (n = 31) showed significantly higher scores compared with the ER-negative group (n = 46) on HAMD total (p = 0.04) and somatic anxiety factor (p = 0.004) scores as well as CGI-S score (p = 0.03). As for QOL measured with the FACT-B, a significantly higher score was found on the Functional Well-Being (FWB) subscale in the ER-positive group (p = 0.001). The relationships were further analysed using generalised linear models (GLM), after controlling for the influence of the current anti-oestrogen treatment. The analysis revealed that ER status was still significantly related to the FWB subscale score of the FACT-B (p = 0.04). However, the HAMD and CGI-S scores were no longer significantly related to ER status after the influence of anti-oestrogen treatment was controlled for.

Conclusion

These results suggest that ER status, which is a well-known biological prognostic factor in breast cancer, may be related to the severity of certain aspects of depressive symptoms or QOL impairment, implying a role of the ER in affective and behavioural regulation. However, anti-oestrogen treatments significantly influence these relationships.

Copyright

Corresponding author

Dr. Bong-Jin Hahm, Department of Psychiatry and Behavioral Sciences, Seoul National University, College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul, 110-744, Republic of Korea. Tel: 82-2-2072-2557; Fax: 82-2-744-7241; E-mail: hahm@snu.ac.kr

References

Hide All
1.Weinberger, T, Forrester, A, Markov, D, Chism, K, Kunkel, EJ. Women at a dangerous intersection: diagnosis and treatment of depression and related disorders in patients with breast cancer. Psychiatr Clin North Am 2010;33:409422.
2.Spiegel, D, Giese-Davis, J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry 2003;54:269282.
3.Bower, JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol 2008;26:768777.
4.Snoj, Z, Akelj, MP, Lièina, M, Pregelj, P. Psychosocial correlates of progesterone receptors in breast cancer. Depress Anxiety 2009;26:544549.
5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies, C, Godwin, Jet al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771784.
6.Razavi, D, Farvacques, C, Delvaux, Net al. Psychosocial correlates of oestrogen and progesterone receptors in breast cancer. Lancet 1990;335:931933.
7.Rosenqvist, S, Berglund, G, Bolund, Cet al. Lack of correlation between anxiety parameters and oestrogen receptor status in early breast cancer. Eur J Cancer 1993;29A:13251326.
8.Chen, X, Zheng, Y, Zheng, Wet al. Prevalence of depression and its related factors among Chinese women with breast cancer. Acta Oncol 2009;48:11281136.
9.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. Washington, DC: American Psychiatric Association, 2000.
10.Oken, MM, Creech, RH, Tormey, DCet al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649655.
11.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:5662.
12.Guy, W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville: National Institute of Mental Health, 1976.
13.Brady, MJ, Cella, DF, Mo Fet al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997;15:974986.
14.Pancheri, P, Picardi, A, Pasquini, M, Gaetano, P, Biondi, M. Psychopathological dimensions of depression: a factor study of the 17-item Hamilton Depression Rating Scale in unipolar depressed outpatients. J Affect Disord 2002;68:4147.
15.Hammond, ME, Hayes, DF, Dowsett, Met al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:27842795.
16.Henry, NL, Stearns, V, Flockhart, DA, Hayes, DF, Riba, M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008;165:12511255.
17.Holsboer, F, Künzel, HE. Clinical Neuroendocrinology. In: Charney DS and Nestler EJ, editors. Neurobiology of Mental Illness, 2nd edn. New York: Oxford University Press, 2004. p. 155170.
18.Rubinow, DR, Schmidt, PJ, Roca, CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998;44:839850.
19.Kulkarni, J, Garland, KA, Scaffidi, Aet al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006;31:543547.
20.Zarate, CA JrSingh, JB, Carlson, PJet al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007;9:561570.
21.Bromberger, JT, Schott, LL, Kravitz, HMet al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). Arch Gen Psychiatry 2010;67:598607.
22.Weiser, MJ, Foradori, CD, Handa, RJ. Estrogen receptor beta in the brain: from form to function. Brain Res Rev 2008;57:309320.

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed